Low Risk of Recurrence in HER2+ Breast Cancer Tumors

A new study has found that patients with specific HER2+ breast cancer tumors have a lower risk of recurrent cancer even five years after diagnosis and without chemotherapy or any treatment.

Researchers reviewed 16,975 cases of breast cancer diagnosed in Kaiser Permanente patients between 2000 and 2006. They found that for patients with the smallest HER2+ tumors (0.5 centimeters or less) who did not receive treatment with the antibody trastuzumab or chemotherapy, the chance of surviving five years without a distant recurrence (cancer that spreads outside the breast to other organs) was 99 percent. A distant recurrence is considered to be more threatening than a local recurrence in the breast.

Tamoxifen reduces breast cancer risk
In a new study, researchers from Cancer Research Insitiute, UK suggests that women on tamoxifen have a reduced breast cancer risk compared to those

For patients with the next size tumor (0.6 to 1 centimeter) the chance of surviving five years without a distant recurrence was 97 percent.

"Our results suggest that trastuzumab therapy may not be needed for patients with HER2+ tumors that are 0.5 centimeters in size or smaller, but should be considered for patients with larger tumors, with stronger consideration as the tumor size nears 1 centimeter," said lead author Lou Fehrenbacher, MD, medical director of Kaiser Permanente Oncology Clinical Trials and oncologist with Kaiser Permanente Vallejo Medical Center. "This is the first large study to demonstrate that the smallest lymph node–negative HER2+ breast cancers have a very low chance of returning."

Typical treatments for small, lymph-node–negative HER2+ tumors include surgery to remove the tumor and radiation therapy, although trastuzumab and chemotherapy are also frequently used to treat patients. HER2+ breast cancer, a subtype that accounts for between 15 and 20 percent of all cases of breast cancer in the United States, has been shown to respond well to trastuzumab. However trastuzumab can lead to heart failure in some women, particularly those who are older and who have other disease conditions.

Consensus on "Combination Therapy" for Breast Cancer
Breast cancer is the commonest cancer among women in the world. There has been some on going controversy on certain aspects of treatment modalities

Unlike larger tumors where distant recurrences are more common, the study found that the risk of local and distant recurrences was similar for these small HER2+ breast cancer tumors.

Source-Eurekalert